Abstract 1996P
Background
Avelumab maintenance therapy is the standard of care for advanced UC (aUC) that has not progressed after prior chemotherapy based on the JAVELIN Bladder 100 phase 3 (JB100) trial. We report primary analyses of PMS data for the safety and effectiveness of avelumab maintenance in pts with aUC in clinical practice in Japan.
Methods
This PMS is a multicenter, observational surveillance of pts with aUC without disease progression after prior chemotherapy who received ≥1 dose of avelumab from Feb 24, 2021, to Dec 7, 2021. Data on safety and effectiveness were collected from the start of avelumab therapy for ≤52 weeks and analyzed by descriptive statistics and Kaplan-Meier methods.
Results
This analysis included 453 pts. Median age was 73.0 years (Q1-Q3, 68.0-78.0), including 180 pts (39.7%) older than 75 years. Primary tumor site was bladder in 244 pts (53.9%) and upper tract in 209 (46.1%). ECOG performance status was 0-1 in 436 pts (96.2%). Prior chemotherapy was gemcitabine + cisplatin in 267 pts (58.9%) and gemcitabine + carboplatin in 163 (36.0%). Response to chemotherapy was complete response in 47 pts (10.4%), partial response in 242 (53.4%), and stable disease in 149 (32.9%). Median observation period was 52.0 weeks (range, 3.6-52.0); at data cutoff (Mar 6, 2024), 128 pts (28.3%) remained on avelumab treatment and 184 pts (40.6%) received subsequent next-line treatment. Adverse drug reactions (ADRs) of safety specifications (SS; any grade) with avelumab occurred in 144 pts (31.8%), including grade ≥3 in 35 (7.7%); the most common any-grade ADRs of SS (≥5% of pts) were infusion reaction in 53 (11.7%) and thyroid dysfunction in 33 (7.3%). 32 pts (9.8%) had an ADR of SS that led to treatment discontinuation. Median overall survival (OS) was not reached and the 1-year OS rate was 77.9% (95% CI, 73.7-81.5).
Conclusions
The primary analysis of this PMS is the largest real-world data set of avelumab maintenance therapy in Asia, observing patients in clinical practice. The safety profile, tolerability, and effectiveness of avelumab maintenance therapy in this PMS were comparable to findings from JB100 and real-world studies from other countries.
Clinical trial identification
the University hospital medical information network clinical trials registry (UMIN-CTR: UMIN 43435).
Editorial acknowledgement
Editorial support was provided by Nucleus Global and was funded by Merck.
Legal entity responsible for the study
Merck Biopharma Co., Ltd., Tokyo, Japan, an affiliate of Merck KGaA.
Funding
This work was supported by Merck Biopharma Co., Ltd., Tokyo, Japan, an affiliate of Merck KGaA (CrossRef Funder ID: 10.13039/100009945) and was previously conducted under an alliance between Merck and Pfizer.
Disclosure
E. Kikuchi: Financial Interests, Personal, Advisory Role: Astellas Pharma, AstraZeneca, Bristol Myers Squibb-Ono Pharmaceutical, Chugai Pharmaceutical, Janssen, Merck, MSD, Pfizer; Financial Interests, Personal, Speaker’s Bureau: Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb-Ono Pharmaceutical, Chugai Pharmaceutical, Janssen, Kissei Pharmaceutical, Kyorin, Merck, MSD, Nippon Kayaku, Nippon Shinyaku, Pfizer, Sanofi, Taiho Pharmaceutical, Takeda, Kyowa Kirin International; Financial Interests, Institutional, Research Funding: Chugai Pharmaceutical, Kissei Pharmaceutical, Kyorin, Kyowa Kirin International, Nippon Kayaku, Nippon Shinyaku, Otsuka, Sanofi, Taiho Pharmaceutical, Takeda. T. Ito, M. Sato, M. Ogi, M. Morita, M. Kajita: Financial Interests, Personal, Full or part-time Employment: Merck Biopharma Co., Ltd., Tokyo, Japan, an affiliate of Merck KGaA. H. Nishiyama: Financial Interests, Personal, Speaker’s Bureau: Astellas Pharma, Merck, MSD, Olympus; Financial Interests, Personal, Research Funding: Chugai Pharmaceutical, Ono Pharmaceutical. All other authors have declared no conflicts of interest.
Resources from the same session
1987P - TROP-2 as a promising ADC target in penile squamous cell carcinoma that promotes cell proliferation by activating AKT through PKCα pathway
Presenter: Yi Tang
Session: Poster session 13
1988P - Enfortumab vedotin (EV) + pembrolizumab (P) outcomes outside clinical trials and biomarkers of benefit in patients (pts) with advanced urothelial carcinoma: Analysis of the UNITE study
Presenter: Tanya Jindal
Session: Poster session 13
1989P - Efficacy of enfortumab vedotin (EV) in patients (pts) with (w) advanced urothelial carcinoma (aUC) who have baseline neuropathy (N) and/or diabetes mellitus (DM): A UNITE study analysis
Presenter: Albert Jang
Session: Poster session 13
1990P - MRG002-HER2 ADC combined with pucotenlimab (a PD-1 inhibitor), in patients with locally advanced or metastatic urothelial carcinoma (UC): Preliminary results of a phase I/II study
Presenter: Chuanliang Cui
Session: Poster session 13
1992P - Real-world (RW) characteristics and outcomes in patients (pts) with muscle-invasive urothelial carcinoma (MIUC) treated with adjuvant nivolumab (NIVO) with or without neoadjuvant chemotherapy (NAC)
Presenter: Hedyeh Ebrahimi
Session: Poster session 13
1993P - A randomized, phase II trial to evaluate the safety and efficacy of eribulin mesylate in combination with atezolizumab compared to atezolizumab alone in subjects with locally advanced or metastatic transitional cell urothelial cancer where cisplatin-based treatment is not an option
Presenter: Anishka D'Souza
Session: Poster session 13
1994P - Updated efficacy profile of the double antibody drug conjugate (DAD) phase I trial: Sacituzumab govitecan (SG) plus enfortumab vedotin (EV) in ≥ second line in metastatic urothelial carcinoma (mUC)
Presenter: Bradley McGregor
Session: Poster session 13
1995P - Insights into second-line (2L) systemic treatment (tx) receipt in patients (pts) with metastatic urothelial carcinoma (mUC): Results of a retrospective observational study in Germany
Presenter: Günter Niegisch
Session: Poster session 13
1997P - Novel biomarker, ephrinB2 (B2), predicts resistance to treatment and poor overall survival (OS) metastatic urothelial carcinoma (mUC)
Presenter: Sarmad Sadeghi
Session: Poster session 13